Sign In

Mina Soryal

Vice President, Commercial Strategy and Corporate Development | FDA Breakthrough Device Designation for Seravue® | Raised > 10M | Published Co-Author Harvard Medical School |

Professional Background

Mina Soryal is an accomplished scientist and entrepreneur in the biotech and pharmaceutical industry, specializing in early cancer detection. With extensive training and funding from the National Cancer Institute, she has developed a unique skill set that encompasses scientific research, regulatory compliance, and commercial strategy. Over the past five years, Mina has significantly contributed to the development of Seravue®, which received FDA Breakthrough Device Designation on June 8th, 2020—a testament to her leadership and innovative vision in the field. She has successfully raised over $8 million from grants and investments, underscoring her ability to attract funding and drive projects forward in the competitive biotech landscape.

Mina’s career reflects a deep commitment to advancing cancer detection methodologies, bridging the gap between scientific research and practical applications in clinical settings. Her expertise spans various domains including scientific research and development (R&D), medical operations, and legal and regulatory matters, making her a well-rounded executive in the healthcare industry. Her leadership roles in multiple organizations demonstrate her strategic thinking and ability to execute complex commercial initiatives.

Education and Achievements

Mina Soryal earned her Master of Science (M.S.) in Biomedical Engineering from Drexel University, where she honed her technical skills and scientific knowledge. Prior to her master's degree, she completed her Bachelor of Science (B.S.) at The College of New Jersey, laying a strong foundation in the principles of engineering and life sciences. This combination of education has equipped her with a robust understanding of the intersection between engineering and biological sciences, essential for her work in cancer detection technology.

In addition to her academic accomplishments, Mina has played pivotal roles in several notable organizations. She previously served as the Vice President of Commercial Strategy and Corporate Development at ImCare Biotech, where she was instrumental in shaping the company’s commercial direction and establishing strategic partnerships. Her experience as a director of Commercial Strategy at the same organization highlights her capacity for leadership and ability to oversee significant projects aimed at improving healthcare outcomes.

Mina also contributed her expertise through advisory roles, including her time as an advisor at Endomedix, Inc. Her involvement in the NIH/Larta Commercialization Accelerator Program (CAP) at the Larta Institute showcases her commitment to fostering innovation in the biotech sector by promoting the transition of scientific discoveries into commercial products.

Notable Contributions

Throughout her career, Mina has demonstrated a strong focus on medical education development, having participated in programs at the University of North Carolina at Chapel Hill. Her involvement in medical education emphasizes her passion for advancing knowledge in the medical community, ensuring that professionals are informed about the latest technological advancements and methodologies in cancer detection and treatment.

Mina’s impressive internship experiences, including her biostatistics internship at the University of North Carolina at Chapel Hill and her Drexel Cooperative Education position at Sparta Science, provided her with critical insights into data-driven decision-making, further bolstering her analytical skills. These experiences have played a vital role in shaping her approach to problem-solving and innovation in the fast-evolving biotech industry.

Impact and Vision

Mina Soryal's impact on early cancer detection through her work with Seravue® and her various leadership roles illustrates her profound commitment to enhancing patient outcomes and transforming healthcare practices. With her diverse expertise and strong educational background, Mina stands as a leading figure in the biotech and pharmaceutical sectors. Her vision of bridging scientific research with commercial viability continues to inspire new approaches to cancer detection, benefiting patients and healthcare providers alike.

Through her contributions, Mina is championing a healthier future, advocating for innovative solutions that not only detect cancer early but also make treatment more accessible and effective. Her journey in the biotech industry is a remarkable narrative of determination, innovation, and an unwavering commitment to advancing healthcare through science.

Related Questions

How did Mina Soryal develop her expertise in early cancer detection technology?
What key factors contributed to Seravue's FDA Breakthrough Device Designation under Mina Soryal's leadership?
What are the implications of Mina Soryal's work for the future of cancer treatment?
How has Mina Soryal's education in biomedical engineering influenced her career path?
In what ways did Mina Soryal's experience at the Larta Institute enhance her skills in commercialization?
Mina Soryal
Add to my network

Location

New York City Metropolitan Area